Fresh from the designation pipeline: orphan drugs recently designated in the European Union (September – November 2013)

Bibliography

• Statland JM, Bundy BN, Wang Y, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 2012;308(13):1357-65
   PubMed Web of Science ®Google Scholar
• Matthews E, Fialho D, Tan SV, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 2010;133(Pt 1):9-22
   PubMedGoogle Scholar
• De Luca A, Pierno S, Liantonio A, et al. New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. Neuromuscul Disord 2004;14(7):405-16
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation: mexiletine hydrochloride for the treatment of myotonic disorders. 2013
   Google Scholar
• Antoniu SA. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010;14(1):21-9
   PubMed Web of Science ®Google Scholar
• Niesters M, Swartjes M, Heij L, et al. The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opin Orphan Drugs 2013;1(1):77-87
   Web of Science ®Google Scholar
• Agency EM. Public summary of opinion on orphan designation: L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser for the treatment of sarcoidosis. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/10/WC500153468.pdf [Accessed December 2013]
   Google Scholar
• Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain 2009;25(4):273-80
   PubMed Web of Science ®Google Scholar
• Birklein F, Riedl B, Sieweke N, et al. Neurological findings in complex regional pain syndromes–analysis of 145 cases. Acta Neurol Scand 2000;101(4):262-9
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation:zoledronic acid for the treatment of complex regional pain syndrome. 2013
   Google Scholar
• Dumitrescu AM, Liao XH, Best TB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004;74(1):168-75
   PubMedGoogle Scholar
• Verge CF, Konrad D, Cohen M, et al. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. J Clin Endocrinol Metab 2012;97(12):4515-23
   PubMedGoogle Scholar
• Agency EM. Public summary of opinion on orphan designation: 3,5-diiodothyropropionic acid for the treatment of Allan-Herndon-Dudley syndrome. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/10/WC500153470.pdf [Accessed December 2013]
   Google Scholar
• Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9(1):77-93
   PubMed Web of Science ®Google Scholar
• Nicox. Pre-clinical results on naproxcinod in models of muscular dystrophy presented at MDA Scientific Conference. Available from: http://www.nicox.com/index.php/en/news-media/news/news-detail/ppreclinical-results-on-naproxcinod-in-models-of-muscular-dystrophy-presented-at-mda-scientific-conferencep [Accessed December 2013]
   Google Scholar
• Agency EM. Public summary of opinion on orphan designation:naproxcinod for the treatment of Duchenne muscular dystrophy. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/10/WC500153471.pdf [Accessed December 2013]
   Google Scholar
• Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004;104(13):4010-19
   PubMed Web of Science ®Google Scholar
• Agency EM. Public summary of positive opinion for orphan designation of lentiviral vector containing the human Wiskott Aldrich syndrome protein genefor the treatment of Wiskott Aldrich syndrome. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006504.pdf [Accessed December 2013]
   Google Scholar
• Dellon ES. Eosinophilic esophagitis. Gastroenterol Clin North Am 2013;42(1):133-53
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Monoclonal antibodies for asthma and chronic obstructive pulmonary disease. Expert Opin Biol Ther 2013;13(2):257-68
   PubMed Web of Science ®Google Scholar
• Kern E, Hirano I. Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs 2013;18(3):353-64
   PubMed Web of Science ®Google Scholar
• Agency EM. Public summary of opinion on orphan designation: human monoclonal antibody against human interleukin 13 for the treatment of eosinophilic oesophagitis. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/11/WC500156184.pdf [Accessed December 2013]
   Google Scholar
• Agency EM. Public summary of opinion on orphan designation:synthetic 12 amino acid peptide designed after subcommissural organ-spondin for the treatment of spinal cord injury. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/11/WC500156185.pdf [Accessed December 2013]
   Google Scholar
• Agency EM. Public summary of opinion on orphan designation:soraprazan for the treatment of Stargardt's disease. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/11/WC500156187.pdf [Accessed December 2013]
   Google Scholar